Through historical documents and moving personal accounts, this film chronicles the nearly two-decade journey from the identification of the HER2 gene to the FDA approval of Herceptin. As the clinical development unfolds, the company faces challenges and conflicts that threaten the future of the drug. The process also takes on new urgency when women with breast cancer and their advocates get early signs the drug may be working. Seeing the potential of the experimental medicine and out of other treatment options, they unite in their demands for access. Despite their differences, Genentech, physicians, breast cancer patients and their advocates must work together if Herceptin is going to gain FDA approval so that all women with HER2-positive breast cancer have access.